Published 2 years ago

Biden administration limits use of two monoclonal antibody treatments

Summary by Ground News

Omicron's resistance to the two leading monoclonal antibody medicines has upended the treatment playbook for COVID-19 in recent weeks. If the drugs prove effective against future variants, the FDA said it could reauthorize their use. The federal action could trigger pushback from some Republican governors who have continued promoting the drugs against the advice of health experts.

0 Articles

All

Left

Center

Right

News18 India

FDA Curbs Use Of Antibody Drugs Sidelined By Omicron

COVID19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they are unlikely to work against the omicron variant that now accounts for nearly all U.S. infections, U.S. health regulators said Monday.

2 years ago·India

Read Full Article

The Independent

FDA revokes approval for Covid antibody drugs that don’t work against Omicron

The Food and Drug Administration (FDA) has revoked its approval for Covid-19 antibody drugs that don’t work against the highly transmissible Omicron variant.

2 years ago·London, United Kingdom

Read Full Article

Associated Press News

FDA halts use of antibody drugs that don't work vs. omicron

WASHINGTON (AP) — COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don't work against the omicron variant that now accounts for nearly all U.S. infections, U.S.

2 years ago·United States

Read Full Article

abc News

FDA halts use of antibody drugs that don't work vs. omicron

U.S. health officials say COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don't work against the omicron variant

2 years ago·United States

Read Full Article

The Washington Post

FDA expected to sharply restrict use of two monoclonal antibodies, spurring a halt in federal shipments of the covid-19 treatments

The therapies by Regeneron and Eli Lilly are not effective against the omicron variant, officials said.

2 years ago

Read Full Article

KRDO

FDA halts use of antibody drugs that don't work vs. omicron

By MATTHEW PERRONE AP Health WriterWASHINGTON (AP) — U.S. health officials say COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don’t work against the omicron variant. The Food and Drug Administration said Monday it is revoking emergency authorization for both drugs. If they prove effective against future variants, the FDA says it can reauthorize their use. The move was expected because both drugmakers h…

2 years ago·Colorado Springs, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.